Rocha, F. V. [UNESP]Barra, C. V. [UNESP]Netto, Adelino Vieira de Godoy [UNESP]Mauro, Antonio Eduardo [UNESP]Carlos, I. Z. [UNESP]Frem, Regina Célia Galvão [UNESP]Ananias, S. R. [UNESP]Quilles, M. B. [UNESP]Stevanato, A. [UNESP]da Rocha, M. C. [UNESP]2014-05-202014-05-202010-05-01European Journal of Medicinal Chemistry. Paris: Elsevier France-editions Scientifiques Medicales Elsevier, v. 45, n. 5, p. 1698-1702, 2010.0223-5234http://hdl.handle.net/11449/7337Complexes of the type [PdX(2)(tdmPz)] {X = Cl(-)(1) Br(-)(2); l(-)(3); SCN(-)(4); tdmPz = 1-thiocarbamoy1-3,5-dimethylpyrazole} have been synthesized and characterized. Compound 1 was formed from the reaction between [PdCl(2)(CH(3)CN)(2)] and 1-thiocarbamoy1-3,5-dimethylpyrazole. Complexes 2, 3 and 4 were obtained by metathesis of the chloro groups from 1 by bromide, iodide and thiocyanate ions, respectively. All the compounds and cisplatin have been tested in vitro by WIT assay for their cytotoxicity against three murine cancer cell lines: mammary adenocarcinoma (LM3 and LMM3) and lung adenocarcinoma (LP07) as well towards normal murine peritoneal exudate cells (PEC). Promising cytotoxic effect against LM3 has been found for 3 showing IC(50) equal to 24.5 mu M which is comparable to the value obtained for cisplatin (30.3 mu M). (C) 2010 Elsevier Masson SAS. All rights reserved.1698-1702engPd(II) complexes1-Thiocarbamoyl-3,5-dimethylpyrazoleSpectroscopyAntitumor activityArtigo10.1016/j.ejmech.2009.12.073WOS:000276695200002Acesso restrito3300223970814448792767705365081985341388134171610000-0002-0057-79640000-0003-1574-681X